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Abstract
Backgrounds: CD26, a multifunctional T cell surface glycoprotein, is a type II transmembrane protein containing only six 
amino acid residues in its cytoplasmic region. In addition to its membrane form, CD26 exists in plasma in a soluble form 
(sCD26), which is thought to be the extracellular domain of the molecule cleaved from the cell surface. Recent studies 
indicated CD26 have an important role in the pathogenesis of asthma, known as Th2 like disease. The function of CD26 in 
the esosinophlic lung disease is not well understood. 
Methods: Serum sCD26 was determined by enzyme-linked immunosorbent assay in patients with acute eosinophilic 
pneumonia, chronic eosinophilic pneumonia (CEP), and sarcoidosis, and in healthy volunteers, to establish its value for 
discriminating between disease entities and as marker of disease activity.
Results: Soluble CD26 was signiﬁ  cantly reduced in CEP and was related to disease severity. In particular, sCD26 was in-
versely correlated with arterial oxygen tension in CEP.
Conclusion: Serum levels of sCD26 might appear to be useful as a new marker of CEP disease activity.
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Introduction
CD26, exhibiting dipeptidyl peptidase IV enzyme activity (DPPIV), is a multifunctional type II trans-
membrane glycoprotein.
1 A soluble CD26 (sCD26), lacking the cytoplasmic tail and transmembrane 
region, is found in serum and other biologic ﬂ  uids.
CD26 belongs to the serine protease family and cleaves N-terminal dipeptides from polypeptides 
with either proline or alanine residues in the penultimate position. Several cytokines and chemokines 
share the X-Pro or X-Ala motif at their N-terminus, including RANTES (regulated on activation normal 
T cell expressed and secreted), eotaxin, monocyte-derived chemokine (MDC), and stromal-derived 
factors (SDF-1).
2 Thus, CD26 modulates the function of certain chemokines such as RANTES, MDC, 
and SDF-1. 
CD26 might stimulate cellular immunity and exhibits a co-stimulatory function.
3 CD26 has an 
important role in the immune system via its ability to bind adenosine deaminase
4 and it mediates signaling 
by direct interaction with the cytoplasmic domain of CD45.
5 Additionally, CD26 interacts with extra-
cellular matrix proteins, collagen, and ﬁ  bronectin.
1
CD26 and T cells have an important role in the pathogenesis of asthma,
6,7 and serum sCD26 is 
signiﬁ  cantly elevated in atopic dermatitis,
8 in which a Th2-like immune response is elicited, although 
the surface expression of CD26 correlates with the production of interferon (IFN)-γ in CD4+ patients 
with a Th1- like immune reaction. There is no information, however, about the levels of sCD26 in the 
serum of patients with acute eosinophilic pneumonia (AEP), chronic eosinophilic pneumonia (CEP), 
and sarcoidosis.
In this study, we examined the serum levels of sCD26 in patients with AEP, CEP, and sarcoidosis, 
and in healthy volunteers, and analyzed the possible correlation between this value and the levels of 
several clinical markers.
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Method
Patients
Patient background is summarized in Table 1. The 
12 patients with eosinophilic pneumonia (5 
patients with AEP and 7 patients with CEP) were 
diagnosed at the Oita University Faculty of Medi-
cine Hospital and related hospitals from 1999 to 
2004. Pulmonary eosinophilia was detected by 
bronchoalveolar lavage (BAL) and transbronchial 
lung biopsy (TBLB) specimens. AEP was diagnosed 
according to the criteria described by Allen and 
Davis:
9 (i) an acute febrile illness of 1–5 days dura-
tion; (ii) hypoxemic respiratory failure; (iii) diffuse 
alveolar or mixed alveolar and interstitial chest 
radiographic inﬁ  ltrates; (iv) eosinophils >25% in 
BAL ﬂ  uid; (v) the absence of parastic, fungal, or 
other infections; (vi) a prompt and complete 
response to corticoids; and (vii) the absence of 
relapse after discontinuation of corticoids. Most 
patients with AEP showed spontaneous improve-
ment, although two patients required corticoste-
roid therapy for a few days. The diagnosis of CEP 
was based on the diagnostic criteria of CEP 
described by Carrington et al.
10 CEP is character-
ized by fever, dyspnea, peripheral blood eosino-
philia, peripheral inﬁ  ltration in chest radiograph 
and inﬁ  ltrated eosinophils in the lung. All patients 
were treated with corticosteroids. We also studied 
a control group of 27 subjects without lung 
disease; 13 patients with sarcoidosis and 14 
healthy volunteers. Sarcoidosis was diagnosed on 
the basis of typical clinical features and the pres-
ence of epithelioid cell granulomas in biopsy 
specimens from the lung, skin, or lymph nodes. 
None of the patients was treated with glucocor-
ticoids before serum sampling was completed. 
Informed consent was obtained from all patients 
and the healthy volunteers.
Determination of serum sCD26
sCD26 concentrations in the serum were measured 
using a commercially available enzyme-linked 
immunosorbent assay kit according to the manu-
facturer’s protocol. A Quantikine kit from R & D 
Systems (Minneapolis, MN) was used to quantify 
sCD26. The minimal detectable level was 
0.016 ng/ml. The following parameters were 
assessed to examine the relation between sCD26 
and clinical parameters; white blood cell counts, 
eosinophil counts, C-reactive protein, IgE, surfac-
tant protein D, surfactant protein A, KL-6, cell 
analysis in BAL, and arterial blood gas data 
(PaO2).
Statistics
The Kruskall-Wallis test was used to compare 
values between groups. Where there was signiﬁ  -
cant difference between groups, data were analyzed 
using Mann-Whitney U test. Correlation coefﬁ  -
cients were determined by Pearson’s linear regres-
sion analysis between sCD26 and various clinical 
parameters. A difference was considered signiﬁ  cant 
when the p-value was less than 0.05.
Results
sCD26 concentrations in the serum 
from patients with various diffuse 
lung diseases
sCD26 concentrations were measured by enzyme-
linked immunosorbent assays. The sCD26 concen-
trations were signiﬁ  cantly decreased in patients with 
CEP (p < 0.05), compared to healthy volunteers 
(Figure 1). CD26 levels in patients with AEP 
tended to be lower than in healthy controls, but there 
was no significant difference in serum sCD26 
Table 1. Subject characteristics.
   Patients  with  eosinophilic  pneumonia
 AEP  CEP  Sarcoidosis  HV
Case 5  7  13  14
(male/female)  (3/2) (3/4) (4/9)  (2/12)
Age ( ± SEM)  18.2 ± 0.53  63.5 ± 1.67  48 ± 2.53  40.3 ± 1.64 
Deﬁ  nition of abbreviations: AEP = acute eosinophilic pneumonia; CEP = chronic eosinophilic pneumonia; Sar = sarcoidosis. Data are 
expressed as mean ± SEM.
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concentrations among AEP, sarcoidosis, and healthy 
volunteers (Figure 1). Prednisone treatment could 
not be responsible for the decline in sCD26, because 
all samples were collected before treatment.
Relationship between sCD26
and various clinical parameters.
There was a signiﬁ  cant correlation between PaO2 
and sCD26 concentrations in the serum from CEP 
(p < 0.01; Figure 2), but not AEP (data not shown). 
These results suggest that serum sCD26 levels 
negatively related to the severity of CEP. 
Discussion
Despite the multifunctionality of CD26, the func-
tion of sCD26 in the immune response is not well 
understood. Upregulation of CD26 on human 
activated lymphocytes by interleukin (IL-12) and 
IL-2, but not by IL-1β, IFN-γ, tumor necrosis factor 
(TNF-α), or IL-4 suggests that CD26 is a marker 
of Th1 response.
11,12 The secretion of sCD26 is not 
affected by IL-12, although translation and prob-
ably translocation of CD26 toward the cell surface 
can be regulated by IL-12.
12 Recent studies demon-
strated that tuberculous infections generate strong 
Th1-like response proﬁ  les. The pleural and serum 
CD26 levels in patients with tuberculous pleurisy 
were signiﬁ  cantly higher than in patients with 
congestive heart failure.
13 Immunohistochemical 
studies also revealed that CD26 is highly expressed 
in tuberculoid leprosy and sarcoidosis, known as 
Th1-like diseases.
14 In our study, however, there 
was no signiﬁ  cant difference in the serum levels 
of sCD26 between patients with sarcoidois and 
healthy volunteers.
The serum levels of sCD26 were signiﬁ  cantly 
decreased in patients with CEP, but not AEP. CEP 
is a rare idiopathic inﬂ  ammatory lung disease 
characterized by eosinophilic inﬁ  ltration of the 
pulmonary interstitium. High levels of IL-5 have 
been documented in the BAL of CEP patients, 
consistent with this being a Th2 type inﬂ  ammatory 
disease.
15 CD26 and T cells have an important role 
in the pathogenesis of asthma.
6,7 In contrast to our 
data, increased levels of sCD26 have been reported 
in patients with presumed Th2-like immune 
disease, such as atopic dermatitis.
8 Recently 
Eltzching et al. also reported that hypoxemia 
induced endothelial CD26 at both the mRNA and 
protein.
16 In the present study, serum levels of 
sCD26 were, however, inversely correlated with 
the disease activity of CEP patients. In another 
immunologic disorders, decreased serum CD26 
correlates with disease severities. For example, in 
rheumatoid arthritis,
17 Crohn’s disease,
18 and 
systemic lupus erythematosus,
19 CD26 levels in 
the serum inverse correlates with disease activity. 
These results indicate that CD26 has an important 
role not only in pathogenesis of Th1 dominant 
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Figure 1. Concentration of sCD26 in serum obtained from patients 
with acute eosinophilic pneumonia (AEP), chronic eosinophilic pneu-
monia (CEP), and sarcoidosis, and healthy volunteers (HV). Sig-
niﬁ  cant differences are shown at the top. 
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Figure 2. Relationship between sCD26 concentrations in the serum 
and PaO2 from patients with chronic eosinophilic pneumonia (CEP) 
(p = 0.0087, r
2 = 0.777).
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diseases, but also in Th2 dominant disease. The 
measurement of serum sCD26 might be of value 
in conjunction with other T cell activation markers 
to monitor both Th1-like and Th2-like immune 
activation. The link between reduced sCD26 levels 
and promotion of inﬂ  ammation has been estab-
lished in rheumatoid arthritis, Crohn’s disease, 
systemic lupus erythematosus, and CEP, but the 
exact role of CD26 remains obscure.
 In conclusion, we demonstrated for the ﬁ  rst 
time that a decrease in sCD26 is inversely associ-
ated with the severity of CEP, although our study 
was limited and preliminary character of ﬁ  ndings. 
Serum levels of CD26 might appear to be useful 
as a new CEP disease activity measure.
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